Combination of Stereotactic Body Radiation Therapy and TKIs: Outcomes in Kidney Cancer
Posted: Monday, May 3, 2021
Stereotactic body radiation therapy combined with tyrosine kinase inhibitors (TKIs) has been demonstrated as a safe treatment and linked to longer overall survival in patients with metastatic renal cell carcinoma than TKIs alone, according to an article published in Frontiers in Oncology. According to Liru He, PhD, of Sun Yat-sen University Cancer Center, China, and colleagues, their findings suggest that “the addition of local therapy may be beneficial for the subgroups of patients with [a] favorable prognosis, such as those with oligometastasis.”
The retrospective study included 190 patients with metastatic renal cell carcinoma. All patients were treated with TKIs, and 85 patients received additional stereotactic body radiation therapy on 144 lesions. Sunitinib was the most common first-line treatment prescribed for 57.9% of patients.
The researchers reported an 82.9% overall response rate to stereotactic body radiation therapy, with a mean follow-up of 13.6 months, and three lesions progressed after treatment. The entire cohort achieved a median overall survival of 36.3 months. Progression-free survival after stereotactic body radiation therapy was 9 months. The authors found the median overall survival was significantly longer with TKIs plus stereotactic body radiation therapy than with TKIs alone (63.2 vs. 29.8 months; P < .001). Large differences in overall survival rates were also observed between the two groups, with 61.2% for combined treatment and 24.6% for TKIs alone.
The researchers noted the safe use of stereotactic body radiation therapy combined with TKIs, with no grade 4 or 5 toxicities. Grade 2 and 3 toxicities were observed in 24 patients and 5 patients, respectively. Furthermore, 8 of 10 grade 3 hematologic toxicities were later resolved.
Disclosure: The authors reported no conflicts of interest.